載入中
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
收盤時
US$10.83
−US$0.17 · -1.55%
盤後
US$11.20
+US$0.37 · +3.42%
10月12日 下午7:55 ET
盤中時間採用ET。市場資料可能有所延遲。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日內區間
目前US$10.83
52週區間
目前US$10.83
盤中時間採用ET。市場資料可能有所延遲。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日內區間
目前US$10.83
52週區間
目前US$10.83
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 9.7萬 USD | — | — | — | — |
| 毛利 | −9.7萬 USD | — | — | — | — |
| 研究與開發 | 4661.6萬 USD | 1433.6萬 USD | 1541.1萬 USD | 2621.4萬 USD | 2332.2萬 USD |
| 銷售、一般及管理費用 | 2117萬 USD | 1602.5萬 USD | 2486.4萬 USD | 1892.1萬 USD | 1235萬 USD |
| 營業費用 | 6778.6萬 USD | 8202萬 USD | 4027.5萬 USD | 4513.5萬 USD | 3567.2萬 USD |
| 利息收入 | 832.3萬 USD | 813.2萬 USD | 462萬 USD | 137.5萬 USD | — |
| 折舊和攤銷 | 9.7萬 USD | — | — | — | — |
| 營業利益 | −6788.3萬 USD | −8202萬 USD | −4027.5萬 USD | −4513.5萬 USD | −3567.2萬 USD |
| 淨利 | −5985.1萬 USD | −7389.7萬 USD | −3511.9萬 USD | −4524.4萬 USD | −4748萬 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$27.17
上漲空間 150.88%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1876.46萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1165.53萬0.12%98.74億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1064.2萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF414.05萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO278.41萬0.02%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA230.55萬0.01%218.24億 USD0.03%US$32.66-0.40%
Dimensional - US Small Cap ETFDFAS193.81萬0.01%338.69億 USD0.31%US$78.17-0.23%
Fidelity Fundamental Small-Mid Cap ETFFFSM187.79萬0.12%14.4億 USD0.43%US$34.02-0.32%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASFidelity Fundamental Small-Mid Cap ETFFFSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
